Published in Cancer Res on May 01, 1975
Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer (1999) 1.56
Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99
Animal models and conserved processes. Theor Biol Med Model (2012) 0.99
Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour. Br J Cancer (1979) 0.96
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol (2009) 0.92
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. Br J Cancer (1988) 0.88
Species differences in tumour responses to cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci (2015) 0.85
Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br J Clin Pharmacol (1995) 0.82
The war on cancer: have we won the battle but lost the war? Oncotarget (2010) 0.79
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS One (2015) 0.79
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials (2015) 0.78
Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations. Br J Cancer (1990) 0.78
The Interactions between L-tyrosine based nanoparticles decorated with folic acid and cervical cancer cells under physiological flow. Mol Pharm (2012) 0.76
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience. J Biopharm Stat (2009) 0.75
Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog. Antimicrob Agents Chemother (1995) 0.75
Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science (1996) 3.84
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity (2001) 3.43
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell (2001) 2.39
An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol (1998) 2.24
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem (1997) 2.00
Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci U S A (1997) 1.91
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med (1973) 1.87
Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol (2000) 1.79
Adriamycin-a review. J Natl Cancer Inst (1975) 1.68
CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci U S A (1999) 1.67
Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol (2000) 1.62
The CD2 ligand LFA-3 activates T cells but depends on the expression and function of the antigen receptor. J Immunol (1988) 1.49
V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol (1999) 1.49
HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med (2001) 1.45
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs (1990) 1.40
Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med (1977) 1.40
Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue. J Virol (2000) 1.39
JAK/STAT signaling by cytokine receptors. Curr Opin Immunol (1998) 1.36
Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J Virol (2001) 1.33
The chemotherapy of urologic cancer. Cancer (1975) 1.32
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev (1976) 1.31
Can automated blood film analysis replace the manual differential? An evaluation of the CellaVision DM96 automated image analysis system. Int J Lab Hematol (2007) 1.28
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis. J Clin Oncol (1984) 1.20
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials (1980) 1.16
Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr Biol (1997) 1.16
Signaling through the interleukin 2 receptor beta chain activates a STAT-5-like DNA-binding activity. Proc Natl Acad Sci U S A (1995) 1.16
Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13
Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer. Cancer Chemother Pharmacol (1980) 1.11
Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease. J Virol (2000) 1.10
Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J Virol (2001) 1.10
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med (1976) 1.10
Interactions of lectins with membrane glycoproteins. Effects of concanavalin A on 5'-nucleotidase. Biochim Biophys Acta (1974) 1.09
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
A trans-receptor mechanism for infection of CD4-negative cells by human immunodeficiency virus type 1. Curr Biol (1999) 1.07
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07
The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes. Proc Natl Acad Sci U S A (1996) 1.06
Single and combination nonhormonal chemotherapy in breast cancer. Cancer (1972) 1.06
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep (1977) 1.04
Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol (2000) 1.04
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Rabbit cells expressing human CD4 and human CCR5 are highly permissive for human immunodeficiency virus type 1 infection. J Virol (1998) 1.02
Glutamine antagonists in chemotherapy. Adv Pharmacol Chemother (1970) 1.01
Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer (1976) 1.00
Heteromerization of the gammac chain with the interleukin-9 receptor alpha subunit leads to STAT activation and prevention of apoptosis. J Biol Chem (1998) 0.99
Calibrated phase II clinical trials in oncology. Stat Med (1987) 0.99
Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
Cloning and function of the rat colonic epithelial K+ channel KVLQT1. J Membr Biol (2001) 0.98
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97
Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity. J Biol Chem (1996) 0.97
Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer (1976) 0.96
Parallel evolution of CCR5-null phenotypes in humans and in a natural host of simian immunodeficiency virus. Curr Biol (1998) 0.95
Shared gamma(c) subunit within the human interleukin-7 receptor complex. A molecular basis for the pathogenesis of X-linked severe combined immunodeficiency. J Clin Invest (1997) 0.95
Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94
Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine. Invest New Drugs (1987) 0.92
Lectin-induced inhibition of plasma membrane 5'-nucleotidase: sensitivity of purified enzyme. Biochem Biophys Res Commun (1977) 0.92
Interleukin-4-specific signal transduction events are driven by homotypic interactions of the interleukin-4 receptor alpha subunit. EMBO J (1996) 0.92
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Phase I clinical trial of spirogermanium. Cancer Treat Rep (1981) 0.91
Combination chemotherapy of advanced Hodgkin's disease. A review. Cancer (1974) 0.91
Campylobacter jejuni as a secondary colonizer of poultry biofilms. J Appl Microbiol (2008) 0.91
Redundant and selective roles for erythropoietin receptor tyrosines in erythropoiesis in vivo. Blood (1998) 0.91
Use of antimicrobial spray applied with an inside-outside birdwasher to reduce bacterial contamination on prechilled chicken carcasses. J Food Prot (1998) 0.90
Streptozotocin and metastatic insulinoma. Ann Intern Med (1971) 0.89
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
Further observations on four subgroups of normal variant short stature. J Clin Endocrinol Metab (1980) 0.89
Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide. J Biol Chem (1999) 0.89
Oligomerization and scaffolding functions of the erythropoietin receptor cytoplasmic tail. J Biol Chem (1999) 0.89
The nitrosoureas--thoughts for the future. Cancer Treat Rep (1976) 0.88
Investigational drugs under study by the United States National Cancer Institute. Cancer Treat Rev (1976) 0.88
Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses (2001) 0.88
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 3 (1973) 0.87
Analysis of interleukin-2-dependent signal transduction through the Shc/Grb2 adapter pathway. Interleukin-2-dependent mitogenesis does not require Shc phosphorylation or receptor association. J Biol Chem (1995) 0.87
Clinical comparison of the nitrosoureas. Cancer (1975) 0.86
Antiestrogens in the treatment of breast cancer. Cancer Treat Rev (1976) 0.86
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev (1977) 0.86
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (1975) 0.86
The California breast cancer law and government-mandated patient education. CA Cancer J Clin (1982) 0.86
Population-based study of small-cell lung cancer. J Clin Oncol (1985) 0.86
Perspectives on research in gynecologic oncology. Cancer (1976) 0.86
Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer (1973) 0.85
Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Neoplasma (1996) 0.85